dLife network reports significant hike in web traffic

Share this article:
Multimedia diabetes network dLife said total visits to its website crossed the one-million mark for the month of November.

The milestone represents a 35% increase versus November 2008 in visits and page views for the diabetes-focused site, the network said, citing Google Analytics stats.

Commenting on the growth, Greg Zegras, dLife COO, told MM&M, “It's a culmination of improvements we've been making to the site over the last 12 months as well as a peak in awareness around [the American Diabetes Association's] American Diabetes Month.”

Zegras said the network has been investing in online tools, including recipes and a food look-up that shows detailed nutritional analyses—information important to patients and caregivers. In addition, an online community was launched last January enabling users to create profiles, share comments and post photos.

The mix has proved attractive to advertisers in the diabetes space. The site's current pharmaceutical brand lineup includes Pfizer's Lyrica, which is approved for treating diabetic nerve pain, as well as Novo Nordisk's insulin line, Lantus (Sanofi-Aventis), Glucagon and Humalog KwikPen (Eli Lilly), Byetta (Amylin/Lilly), Avandia (GlaxoSmithKline) and Actos (Takeda).

dLife, whose media outlets include the dLifeTV program, said the following companies have recently aired ads against the show: Merck for Januvia, Sanofi-Aventis for Lantus and Roche for AccuCheck. The dLifeTV program appears on CNBC.
Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...